$3.79
▲ +1.9% Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus
Overview
52-week range
$1.35
$4.60
75% of range
Avg surprise (last 3)
+47.4%
Avg reaction (last 2)
-1.5%
0% positive
Latest IV / EM
322%
EM ±73.7% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-0.16 | $-0.22 | +27.3% | -100.0% | -0.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.21 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.13 | $-0.23 | +43.5% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.08 | $-0.28 | +71.4% | — | -2.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.28 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.92 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.65 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.33 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-2.74 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.19 | -$0.13 | -46.1% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-21M | — | $-19M | $-25M | $-18M | — | $-21M | $-15M |
| Net income | $-39M | — | $-17M | $-11M | $-6M | — | $77M | $-45M |
| EPS (diluted) | $-0.33 | — | $-0.21 | $-0.13 | $-0.08 | — | $-0.28 | $-0.92 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $6M | $23M | $4M | $6M | $8M | $21M | $7M | $26M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $114M | $136M | $96M | $111M | $128M | $144M | $82M | $87M |
| Total assets | $147M | $169M | $130M | $145M | $161M | $177M | $115M | $120M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $46M | $32M | $39M | $39M | $47M | $59M | $39M | $129M |
| Total equity | $45M | $81M | $35M | $50M | $59M | $62M | $20M | $-64M |